US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roche Holding Ltd

40.86

+0.10000.25%

Post-market: 40.860.00000.00%16:00 EDT

Volume:979.09K

Turnover:39.88M

Market Cap:264.53B

PE:26.35

High:40.89

Open:40.51

Low:40.51

Close:40.76

Loading ...

Overview Company News Filings

Top Analyst Reports for Coca-Cola, Abbott & RTX

Roche's $50 Billion U.S. Investment Signals Trump's Tariff Strategy Is Working, AlphaValue Says -- Market Talk

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom -- Update

Roche Sales Expected to Rise, Eye Drug Vabysmo in Focus -- Earnings Preview

Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

EU Approval of Roche's Lymphoma Drug Is Good News But No Surprise -- Market Talk

Roche Holding AG Rises Thursday, Underperforms Market

Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs -- Update

Pharma Stocks Drop After Trump Threatens Tariffs on Medicines -- WSJ

Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

Trump teases targeted tariffs on overseas drug manufacturers

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

Roche to Launch Late-Stage Trial for Alzheimer's Drug Candidate After Positive Study Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RHHBY/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":40.86,"timestamp":1749240000000,"preClose":40.76,"halted":0,"volume":979086,"hourTrading":{"tag":"盘后","latestPrice":40.86,"preClose":40.86,"latestTime":"16:00 EDT","volume":149,"amount":6088.14,"timestamp":1749240005714},"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Market Closed","change":0.1,"latestTime":"06-06 16:00:00 EDT Delay","open":40.51,"high":40.89,"low":40.51,"amount":39881288.591699965,"amplitude":0.009323,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":40.76,"volumeRatio":0.9515158288218268},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":0.9515158288218268,"shares":6474029800,"dividePrice":1.34,"high":40.89,"amplitude":0.009323,"preClose":40.76,"low":40.51,"week52Low":33.3,"pbRate":"6.84","psRate":"3.48","week52High":44.31,"institutionHeld":0,"latestPrice":40.86,"eps":1.550894,"divideRate":0.032795,"volume":979086,"delay":15,"ttmEps":1.550894,"open":40.51,"prevYearClose":34.88,"prevWeekClose":40.3,"prevMonthClose":40.3,"prevQuarterClose":41.15,"fiveDayClose":40.3,"twentyDayClose":39.11,"sixtyDayClose":43.56},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529038660","title":"Top Analyst Reports for Coca-Cola, Abbott & RTX","url":"https://stock-news.laohu8.com/highlight/detail?id=2529038660","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529038660?lang=en_us&edition=fundamental","pubTime":"2025-04-24 05:37","pubTimestamp":1745444220,"startTime":"0","endTime":"0","summary":"Wednesday, April 23, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Coca-Col","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-analyst-reports-coca-cola-213700935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0787776722.HKD","LU0098860793.USD","LU1003077747.HKD","LU1061106388.HKD","IE00B42XCP33.USD","CNQ","LU0912757837.SGD","FE","LU1988902786.USD","BK4587","LU2237443465.HKD","ITIC","RTX","LU0642271901.SGD","WRB","HTH","LU0225283273.USD","LU0661504455.SGD","SG9999014567.USD","WDC","CTAS","JAZZ","LU0302445910.USD","LU0708995401.HKD","ADI","LU1929549753.HKD","LU1069347547.HKD","RHHBY","LU0553294199.USD","IE0009355771.USD","IE00B5949003.HKD","LOW","03165","LU2237957902.USD","IE00BD6J9T35.USD","LU2125154935.USD","AMNF","LU2552382058.USD","KO","BK4543","LU1035773651.USD","ABT","LU2264538146.SGD","LU2360032135.SGD","LU1732800096.USD","LU1064131342.USD","AFRM"],"gpt_icon":1},{"id":"2529300917","title":"Roche's $50 Billion U.S. Investment Signals Trump's Tariff Strategy Is Working, AlphaValue Says -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2529300917","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529300917?lang=en_us&edition=fundamental","pubTime":"2025-04-22 21:03","pubTimestamp":1745326980,"startTime":"0","endTime":"0","summary":"1300 GMT - Roche's $50 billion U.S. investment signals that president Trump's pressure tactics amid tariffs prospects are proving effective, AlphaValue analysts say in a note. The Swiss pharma giant's five-year $50 billion pledge in U.S. manufacturing and R&D joins a growing trend of companies increasing investment in the country, they say. Roche shares fall 2% to 250.60 Swiss Francs. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STRK","BK4007","BK4023","BK4588","BK4595","BK4596","BK4585","RHHBY","BK4516","03165","BK4600"],"gpt_icon":1},{"id":"2529459379","title":"Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2529459379","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529459379?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:51","pubTimestamp":1745319060,"startTime":"0","endTime":"0","summary":"Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad.Roche will invest $50 billion over five years, including in a new factory to make glucose-monitoring devices and a new plant for weight-loss drugs. The Swiss drugmaker said the investments will create 12,000 construction and other jobs.Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies. Fujifilm's plant in Holly Springs, N.C., will make bulk drug material for Regeneron medicines.Chief Executive Leonard Schleifer said the deal would bolster the supply of Regeneron's medicines \"while generating economic growth and high-paying jobs for America itself.\" Regeneron also makes medicines in New York State and Limerick, Ireland.In additi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2529344328","title":"Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2529344328","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529344328?lang=en_us&edition=fundamental","pubTime":"2025-04-22 16:15","pubTimestamp":1745309700,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical giant Roche plans to invest $50 billion in the U.S. over the next five years, the latest major spending commitment by a big drugmaker as the industry faces President Trump's tariff threats.Pharma companies have in recent months set out plans to ramp up investments in the U.S. to boost local production and create jobs as the Trump administration prepares to impose tariffs on medicine imports--which have so far been exempted from such levies--and seeks to revive domestic manufacturing.Roche's move follows in the footsteps of a pledge by Swiss peer Novartis to spend $23 billion over the next five years to expand its footprint in the U.S. earlier this month. Meanwhile, last month Johnson & Johnson said it was increasing U.S. spending to more than $55 billion over the next four years, while Eli Lilly in February outlined plans for a $27 billion investment to build four new manufacturing plants in the country.The company currently has 15 R&D centers and 13 manufacturing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom -- Update","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RHHBY","03165"],"gpt_icon":0},{"id":"2529034436","title":"Roche Sales Expected to Rise, Eye Drug Vabysmo in Focus -- Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2529034436","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529034436?lang=en_us&edition=fundamental","pubTime":"2025-04-22 16:15","pubTimestamp":1745309700,"startTime":"0","endTime":"0","summary":"Roche is scheduled to report results for the first quarter on Thursday. Here is what you need to know.SALES FORECAST: The group's sales should come to 15.33 billion Swiss francs , according to consensus estimates of 14 analysts compiled by Visible Alpha. This compares with 14.39 billion francs the year before.The stock fell 1.1% since the start of 2025 but is up 15% over the past year.--Beyond tariffs, investor attention centers around key growth drivers and the potential for late-stage pipeline readouts, UBS analysts said. Investors will look at commentary on blockbuster eye drug Vabysmo's sales performance, which could slow down in the U.S. due to potential Medicare funding issues affecting patients, UBS and Barclays analysts said.Both brokers expect that solid growth trends for multiple sclerosis drug Ocrevus and hemophilia injection Hemlibra have continued in the first quarter. Key late-stage trials include astegolimab in chronic obstructive pulmonary disease, early breast cancer e","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"gpt_icon":0},{"id":"2528723115","title":"Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars","url":"https://stock-news.laohu8.com/highlight/detail?id=2528723115","media":"Quartz","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528723115?lang=en_us&edition=fundamental","pubTime":"2025-04-17 23:20","pubTimestamp":1744903245,"startTime":"0","endTime":"0","summary":"The first GLP-1 pill could be in medicine cabinets sooner than expected.Eli Lilly  announced Thursday that its daily obesity pill, orforglipron, met company goals in the first of several late-stage trials — helping patients with Type 2 diabetes lower their blood sugar while causing weight loss. The results were comparable with other GLP-1 injections on the market, such as Ozempic and Mounjaro.Orforglipron could give Lilly a key advantage over other pharmaceutical giants in the GLP-1 realm. Lilly’s stock was up 11% in premarket trading. Novo Nordisk , which makes Ozempic, was down 6%.The results are pivotal: While the GLP-1 class of medication has become a blockbuster on the market , they’re expensive, must be injected, and need to be kept refrigerated. A pill version would be a more convenient option that could be much more widely used.The study measured weight loss as a secondary goal. Patients who received orforglipron also reported weight loss — up to 16 pounds without","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lillys-weight-loss-pill-152045475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SGXZ81514606.USD","LU2750360641.GBP","SG9999015952.SGD","LU0203201768.USD","LU2237438978.USD","SG9999014906.USD","LU1868837300.USD","LU0122379950.USD","LU0823416689.USD","LU1280957306.USD","SG9999018857.SGD","LU2357305700.SGD","NVO","LU1366192091.USD","LU2750360997.AUD","IE00B2B36J28.USD","IE00BKVL7J92.USD","03165","LU0466842654.USD","LU1267930730.SGD","LU1720051017.SGD","LU0471298694.HKD","LU0114720955.EUR","SG9999017495.SGD","LU0820561909.HKD","IE0004445239.USD","LU1548497426.USD","IE00B4R5TH58.HKD","LU2602419157.SGD","LLY","LU0289739699.SGD","LU0354030438.USD","RHHBY","LU2361045086.USD","LU2237443549.SGD","LU0882574139.USD","GB00BDT5M118.USD","CDC","BK4588","LU0106261372.USD","LU1868836914.USD","LU0109391861.USD","LU0456855351.SGD","LU1127390331.HKD","LU0006306889.USD","LU0256863902.USD","LU0320765059.SGD","LU1551013342.USD","LU1917777945.USD","LU2361044865.SGD"],"gpt_icon":1},{"id":"2528474479","title":"Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2528474479","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528474479?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:15","pubTimestamp":1744895700,"startTime":"0","endTime":"0","summary":"J&J JNJ began the earnings season for the drug and biotech sector this week. Pfizer PFE announced the discontinuation of its danuglipron weight loss pill program. The European Commission granted marketing authorization for the expanded use of Roche’s RHHBY cancer drug, Columvi. Sanofi SNY provided an update on its respiratory pipeline.Here's a recap of the week’s most important stories.J&J beat first-quarter estimates for both earnings and sales. Adjusted earnings of $2.77 per share rose 2.2% from the year-ago period. Sales of $21.89 billion rose 2.4% from the year-ago quarter. Innovative Medicines segment sales rose 2.3% year over year to $13.87 billion. MedTech segment sales came in at $8.02 billion, up 2.5% from the year-ago period.The U.S. Centers for Disease Control and Prevention’s  Advisory Committee on Immunization Practices recommended the expanded use of Pfizer and GSK’s respiratory syncytial virus  vaccines, Abrysvo and Arexvy, respectively, in adults aged 50 to 59 at increa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-j-js-131500764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0985481810.HKD","SG9999003800.SGD","LU0170899867.USD","IE00B19Z3B42.SGD","IE00BVYPNV92.GBP","LU2505996509.AUD","SG9999001176.USD","LU0795875169.SGD","LU1162221912.USD","LU0058720904.USD","LU1244550494.USD","IE00BFXG1179.USD","LU0792757196.USD","LU0985320562.USD","LU1778281490.HKD","SGXZ57979304.SGD","CDC","LU2430703178.SGD","LU1585245621.USD","03165","LU0122379950.USD","IE00BGHQF631.EUR","LU1066051811.HKD","IE00BSNM7G36.USD","LU0203345920.USD","SG9999001440.SGD","BK4550","SNY","LU2129689605.HKD","IE0002141913.USD","BK4568","LU0098860793.USD","JNJ","LU1718418525.SGD","LU2430703251.USD","IE00BN8TJ469.HKD","PFE","IE00B19Z3581.USD","LU2347655156.SGD","RHHBY","SG9999013999.USD","IE00BBT3K403.USD","IE00BDGV0183.EUR","IE00BFTCPJ56.SGD","LU1244550221.USD","LU1066051225.USD","BK4581","LU1032466523.USD","LU0345769128.USD","LU2430703095.HKD"],"gpt_icon":1},{"id":"2527217592","title":"SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2527217592","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527217592?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:32","pubTimestamp":1744803120,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of limb-girdle muscular dystrophy , a group of rare genetic disorders marked by progressive muscle weakness.Following positive FDA feedback, the company is advancing a fourth LGMD program to clinical development. Sarepta will soon start screening and dosing patients in the first-in-human clinical SRP-9005-101  study, to evaluate its investigational gene therapy SRP-9005 for LGMD type 2C/R5 .SRPT also announced completion of enrollment and dosing in the phase I proof-of-concept SRP-9004-102  study, which is evaluating SRP-9004 in patients with LGMD type 2D/R3 .The company also reiterated its plans to report data from the late-stage EMERGENE study, evaluating SRP-9003 in patients with LGMD type 2E/R4 , by first-half 2025. This study’s primary endpoint is the biomarker expression of the beta-sarcoglycan protein, whose absence is the sole cause of the disease. Following a pre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-provides-pipeline-updates-rare-113200363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","LU1559883803.SGD","SRPT","IE00BJJMRZ35.SGD","CTMX","IE0009355771.USD","BK4585","ANIP","IE00B2B36J28.USD","BK4007","IE0002141913.USD","03165","RHHBY","IE00BJT1NW94.SGD","LU0566484027.USD","BK4139"],"gpt_icon":0},{"id":"2527467116","title":"U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2527467116","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527467116?lang=en_us&edition=fundamental","pubTime":"2025-04-15 17:55","pubTimestamp":1744710900,"startTime":"0","endTime":"0","summary":"0955 GMT - A U.S. investigation into pharmaceutical imports and potential tariffs in the coming months will likely limit clarity from pharma companies during their 1Q results, Barclays analysts say in a note. The investigation, initiated April 1, aims to assess the national security implications of pharmaceutical imports, including finished generics, nongenerics and active pharmaceutical ingredients, and has to be finalized in around nine months. \"With Pharma having been excluded from the initial reciprocal tariffs and it being our house view that some sort of Commerce Department investigation being required for these sectoral tariffs, this isn't too surprising but at least provides some timing framing,\" they say. Barclays analysts estimate that AstraZeneca, Roche and Grifols appear most insulated, whereas GSK and Sandoz look most exposed to a potential tariff risk. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4568","LU2236285917.USD","BK4532","LU0320765992.SGD","GSK.UK","BK4585","GRFS","LU0889565916.HKD","BK4139","BK4007","LU1829250122.USD","LU2456880835.USD","BK4156","LU2417539215.USD","RHHBY","BK4588","AZN","03165","GSK","LU2462157665.USD"],"gpt_icon":0},{"id":"2527183872","title":"EU Approval of Roche's Lymphoma Drug Is Good News But No Surprise -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2527183872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527183872?lang=en_us&edition=fundamental","pubTime":"2025-04-14 16:57","pubTimestamp":1744621020,"startTime":"0","endTime":"0","summary":"0857 GMT - Swiss pharma giant Roche's lymphoma drug Columvi getting EU approval as a second-line treatment is positive but expected, Vontobel analyst Stefan Schneider says in a note. Columvi is the first treatment for patients with relapsed or refractory diffuse B-cell lymphoma in Europe who didn't respond to initial treatment. Shares rise 2.5% to 250 Swiss francs.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","BK4156","BK4007","RHHBY"],"gpt_icon":0},{"id":"2526513750","title":"Roche Holding AG Rises Thursday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2526513750","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526513750?lang=en_us&edition=fundamental","pubTime":"2025-04-11 00:17","pubTimestamp":1744301820,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  rose 3.2% to CHF243.00 Thursday on what proved to be an overall positive trading session for the stock market, with the Swiss SMI Index  rising 3.3% to 11,244.59.Roche Holding AG closed CHF70.80 short of its 52-week high of CHF313.80, which the company achieved on March 12, 2025.Trading volume was 1,892,499, compared to the 50-day average trading volume of 1,455,718.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","AG"],"gpt_icon":0},{"id":"2526899425","title":"Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526899425","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526899425?lang=en_us&edition=fundamental","pubTime":"2025-04-10 15:36","pubTimestamp":1744270560,"startTime":"0","endTime":"0","summary":"0736 GMT - European pharma stocks jump at Thursday's market open, mirroring broader market gains, after U.S. President Trump announced a 90-day pause on so-called reciprocal tariffs. The Stoxx 600 health index surges around 7.2%, outpacing the wider Stoxx 600's 1.2% rise. While pharmaceuticals have so far been spared, Trump reiterated on Tuesday that tariffs on imported medicines remain a possibility. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","AZN","LU2462157665.USD","BK4588","LU0211331839.USD","LU0109394709.USD","LU0208291251.USD","LU1829250122.USD","BK4568","BK4532","IE0009355771.USD","RHHBY","BK4578","BK4007","03165","NVS","LU0320765992.SGD","IE0002141913.USD","GSK","LU0320765489.SGD","BK4585","LU2236285917.USD","IE00B4R5TH58.HKD","LU0070302665.USD","IE00BFXG1179.USD","LU2417539215.USD","SNY","LU0889565916.HKD","IE00BFTCPJ56.SGD","LU2456880835.USD","GSK.UK","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2526963233","title":"Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2526963233","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526963233?lang=en_us&edition=fundamental","pubTime":"2025-04-09 23:03","pubTimestamp":1744210980,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks sank lower Wednesday after President Trump doubled down on his promise to slap tariffs on a long-exempt industry, causing market turmoil globally.The Dow Jones U.S. Pharmaceuticals Index slipped 3.7% to 768.75 Wednesday morning, at one point hitting a 52-week low of 766.61. AbbVie shares fell 5.9% to $165.34, while Eli Lilly, Merck and Pfizer all declined about 3%.In European morning trade, the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--dropped 3.1% Wednesday, also touching a year low earlier in the session.Switzerland's Roche and Novartis, the U.K.'s AstraZeneca, Denmark's Novo Nordisk and France's Sanofi were all down more than 5% in morning trade. Japan's Daiichi Sankyo and Takeda Pharmaceutical retreated 6% and 4.7%, respectively, while Australia's CSL shed 5%.The pharma sector had been spared last week from Trump's sweeping tariff plan, which kicked in Wednesday, and drug companies have been exempt","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2552382132.HKD","RHHBY","LU0553294199.USD","LU2237443382.USD","SG9999015945.SGD","LU2462157665.USD","LU0208291251.USD","PFE","LU0061475181.USD","LU2347655156.SGD","LU0943347566.SGD","LU0385154629.USD","LU0882574139.USD","MRK","SNY","LU0070302665.USD","DSNKY","IE00B19Z3581.USD","BK7501","CSL.AU","LU1720051108.HKD","03165","LU0708995401.HKD","LU1366192091.USD","TAK","BK7511","LU2602419157.SGD","SG9999002224.SGD","IE00BZ1G4Q59.USD","SG9999001440.SGD","LU1035775433.USD","LU0029864427.USD","NVO","LU0265550359.USD","LU1829250122.USD","LU1066051811.HKD","AZN","ABBV","LU1496350171.SGD","LU0109391861.USD","IE00B3PB1722.GBP","LU1804176565.USD","LU2129689605.HKD","NVS","LLY","LU0158827948.USD","LU1983299246.USD","LU1003077747.HKD","IE00BVYPNV92.GBP","IE00BJLML261.HKD"],"gpt_icon":1},{"id":"2526356596","title":"Pharma Stocks Drop After Trump Threatens Tariffs on Medicines -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2526356596","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526356596?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:17","pubTimestamp":1744193820,"startTime":"0","endTime":"0","summary":"Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.-- Switzerland's Roche and Novartis, the U.K.'s AstraZeneca and GSK and France's Sanofi were all down 5% or more in European midday trade.-- Japan's Daiichi Sankyo and Takeda Pharmaceutical closed 6% and 4.7% lower, respectively.-- In U.S. premarket trading, Eli Lilly, Merck and Pfizer all fell at least 1%.The drug sector was spared from Trump's sweeping tariff plan that kicked in today, but the president's remarks at a Tuesday dinner with House Republicans suggested levies could come very shortly.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0234572021.USD","IE0002270589.USD","LU0225284248.USD","LU2462157665.USD","SG9999001176.USD","IE00B4R5TH58.HKD","LU0225771236.USD","RHHBY","AZN","BK4599","BK4568","LU2417539215.USD","BK4588","BK4534","SG9999003800.SGD","BK4007","IE00B19Z3581.USD","IE0009355771.USD","IE00BLSP4239.USD","LU0208291251.USD","GSK","LU0070302665.USD","LU1066053197.SGD","NVS","SG9999002232.USD","BK4533","LU1023059063.AUD","SG9999011175.SGD","SNY","IE00B19Z3B42.SGD","SG9999013999.USD","LU0321505868.SGD","IE00BJT1NW94.SGD","LU2236285917.USD","MDCO","03165","LU1894683348.USD","LU0170899867.USD","LU2456880835.USD","LU1829250122.USD","LU0058720904.USD","LU1894683264.USD","GSK.UK","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","IE00BFXG1179.USD","BK4532"],"gpt_icon":1},{"id":"2526681355","title":"Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526681355","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526681355?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:03","pubTimestamp":1744192980,"startTime":"0","endTime":"0","summary":"1003 GMT - Roche's sales performance of its eye drug Vabysmo will be closely watched among its 1Q results, Barclays analysts say in a note. They anticipate a U.S. sales slowdown due to potential Medicare funding issues affecting Vabysmo patients. While Roche has outperformed its European peers in the large-cap pharmaceutical sector this year, recent disappointing trial results with its multiple sclerosis drug HD Ocrevus and safety worries regarding its Elevidys treatment for Duchenne Muscular Dystrophy have created headwinds. Barclays expects Roche to reaffirm its full-year guidance, and developments around its experimental oral weight-loss drug orforglipron to move the share price more than its 1Q results. Roche shares fall 6% to 234.80 Swiss francs. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"gpt_icon":0},{"id":"2526133062","title":"Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2526133062","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526133062?lang=en_us&edition=fundamental","pubTime":"2025-04-09 17:24","pubTimestamp":1744190640,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks took a hit after U.S. President Trump said tariffs on pharma imports will be unveiled very shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil globally.In European morning trade, the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--was down 4.5%, against a 2.7% fall for the broader Stoxx Europe 600. The falls mirrored a selloff among pharma stocks in Asia.Switzerland's Roche and Novartis, the U.K.'s AstraZeneca and GSK and France's Sanofi were down 5% or more in morning trade. Japan's Daiichi Sankyo and Takeda Pharmaceutical closed 6% and 4.7% lower, while Australia's CSL shed 5%.The pharma sector was spared from Trump's sweeping tariff plan last week, which kicked in on Wednesday, but the U.S. president had previously pledged to impose tariff on pharma products and his remarks at a Tuesday dinner with House Republicans suggested levies could come soon.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK","LU1718418525.SGD","LU1093756168.USD","LU2264538146.SGD","LU1732799900.SGD","LU0061475181.USD","GSK","IE00BDGV0183.EUR","PFE","SG9999014567.USD","CSL.AU","LU0289739699.SGD","LU2129689605.HKD","MDCO","DSNKY","LU0965509101.SGD","TAK","LU0417517546.SGD","SG9999002224.SGD","03165","LU1934455277.USD","LU1551013342.USD","LU0965508806.USD","LU2133065610.SGD","LU0079474960.USD","LU2237443978.SGD","BK4581","ABBV","LU1988902786.USD","LU0320765059.SGD","SGXZ99366536.SGD","SG9999014575.USD","LU0203201768.USD","IE0009355771.USD","LU1035773651.USD","LU1720051108.HKD","LU1989771016.USD","LU0471298694.HKD","LLY","LU1868836591.USD","BK4559","GSK.UK","SG9999017495.SGD","BK4007","NVS","RHHBY","SG9999013999.USD","LU1366192091.USD","SG9999015986.USD","LU0965509283.SGD"],"gpt_icon":1},{"id":"2526382960","title":"Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526382960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526382960?lang=en_us&edition=fundamental","pubTime":"2025-04-09 15:23","pubTimestamp":1744183380,"startTime":"0","endTime":"0","summary":"0723 GMT - Pharma stocks take a hit in early morning European trade after U.S. President Trump said at a Tuesday dinner with House Republicans that tariffs on pharmaceuticals will be imposed very shortly. British AstraZeneca and GSK slump 3.9% and 2.8%, respectively. Swiss Roche and Novartis fall 4.8% and 4.1%, respectively. French Sanofi is down 4.5%. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00B2B36J28.USD","LU1829250122.USD","GSK","AZN","BK4588","BK4532","BK4007","GSK.UK","IE0009355771.USD","BK4578","LU2417539215.USD","LU0320765489.SGD","BK4568","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU2236285917.USD","LU0070302665.USD","NVS","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","LU0211331839.USD","RHHBY","IE00BFTCPJ56.SGD","LU2456880835.USD","LU2462157665.USD","LU0208291251.USD","IE00BJT1NW94.SGD","BK4585","03165"],"gpt_icon":0},{"id":"2526580918","title":"Trump teases targeted tariffs on overseas drug manufacturers","url":"https://stock-news.laohu8.com/highlight/detail?id=2526580918","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526580918?lang=en_us&edition=fundamental","pubTime":"2025-04-09 11:32","pubTimestamp":1744169520,"startTime":"0","endTime":"0","summary":"'We're going to be announcing, very shortly, a major tariff on pharmaceuticals,' he tells attendees of a Republican fundraising dinner. With the next set of White House-imposed tariffs just hours away from taking effect - including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. - President Donald Trump indicated he intends to roll out more product-specific tariffs down the road.The Republican president has previously threatened import taxes on goods like copper, lumber and pharmaceutical drugs - all of which are currently exempt from Trump's \"reciprocal\" levies.Speaking Tuesday evening at a Republican National Congressional Committee dinner, Trump called out one particular industry in his crosshairs: pharmaceuticals XPH PJP IHE.Trump boasted at the NRCC event, an important venue for fundraising by House Republicans, that he was about to impart \"breaking news.\". Trump went on to observe that the U.S. no longer produces many of the p","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IHE","BK4568","LU2236285917.USD","BK4532","LU2322448957.HKD","LU2473716301.USD","LU2322448791.USD","LU0320765992.SGD","LU2272731782.SGD","LU0320765489.SGD","GSK.UK","BK4585","XPH","LU0208291251.USD","BK4578","LU0889565916.HKD","IE00BFXG1179.USD","IE00BJT1NW94.SGD","BK4007","IE00B4R5TH58.HKD","LU1829250122.USD","LU2272731600.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU1992135472.HKD","LU1992135399.USD","IE0002141913.USD","PJP","LU2456880835.USD","LU0070302665.USD","LU2417539215.USD","SNY","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","LU2272731865.HKD","RHHBY","BK4588","AZN","03165","IE00B5TLWC47.USD","NVS","GSK","LU2462157665.USD"],"gpt_icon":0},{"id":"2524420475","title":"SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524420475","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524420475?lang=en_us&edition=fundamental","pubTime":"2025-04-04 19:29","pubTimestamp":1743766140,"startTime":"0","endTime":"0","summary":"Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy . The therapy has been developed in collaboration with pharma giant Roche RHHBY.This hold has been placed in response to a patient’s death post-treatment with Elevidys, which was reported last month. Though the death was due to acute liver failure , Sarepta believes that the patient’s recent CMV infection might have contributed to the outcome. Investigation is still ongoing.In a letter to the World Duchenne Organization, Roche mentioned that the companies are pausing enrollment and dosing of study participants in three studies evaluating the therapy at the EU study sites. This hold will remain ‘until the analysis into the cause of death is complete.’。SRPT and RHHBY entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, Sarepta retains the rights to market the gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-stock-down-ema-places-112900759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","IE0009355771.USD","SRPT","IE0002141913.USD","IE00BJJMRZ35.SGD","03165","ANIP","IE00BJT1NW94.SGD","BK4139","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4585","BK4007","RHHBY"],"gpt_icon":0},{"id":"2524883250","title":"Roche to Launch Late-Stage Trial for Alzheimer's Drug Candidate After Positive Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524883250","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524883250?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:30","pubTimestamp":1743687000,"startTime":"0","endTime":"0","summary":"Roche Holding said it will initiate a late-stage trial for its Alzheimer's drug candidate trontinemab later this year after its mid-stage study showed positive results.The Swiss pharma giant said Thursday during a conference that its experimental treatment showed a reduction of amyloid plaques--protein clumps in the brain that contribute to the disease's progression--in patients with Alzheimer's disease.In addition, its plasma diagnostics test Elecsys pTau181 demonstrated the ability to determine whether or not someone has amyloid pathology, one of the hallmarks of Alzheimer's disease.\"We are pleased with the progress across our Alzheimer's portfolio as we move ahead with a Phase III trontinemab program and continue to expand our diagnostic solutions,\" Levi Garraway, Roche's Chief Medical Officer said.More than 55 million people worldwide are living with dementia, of which around 70% have Alzheimer's. Up to three-quarters of people experiencing symptoms of Alzheimer's remain undiagnose","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","SSI","BK4007","03165"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":114,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-07-24","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1753344000000,"name":null,"time":"Pre-Market","dateTimestamp":1753329600000,"actualEps":null},{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1745899200000}}}